Tanei, T.; Yamamoto, S.; Maesawa, S.; Nishimura, Y.; Ishizaki, T.; Nagashima, Y.; Ito, Y.; Hashida, M.; Suzuki, T.; Hamasaki, H.;
et al. Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice. Neurol. Int. 2025, 17, 62.
https://doi.org/10.3390/neurolint17050062
AMA Style
Tanei T, Yamamoto S, Maesawa S, Nishimura Y, Ishizaki T, Nagashima Y, Ito Y, Hashida M, Suzuki T, Hamasaki H,
et al. Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice. Neurology International. 2025; 17(5):62.
https://doi.org/10.3390/neurolint17050062
Chicago/Turabian Style
Tanei, Takafumi, Shun Yamamoto, Satoshi Maesawa, Yusuke Nishimura, Tomotaka Ishizaki, Yoshitaka Nagashima, Yoshiki Ito, Miki Hashida, Takahiro Suzuki, Hajime Hamasaki,
and et al. 2025. "Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice" Neurology International 17, no. 5: 62.
https://doi.org/10.3390/neurolint17050062
APA Style
Tanei, T., Yamamoto, S., Maesawa, S., Nishimura, Y., Ishizaki, T., Nagashima, Y., Ito, Y., Hashida, M., Suzuki, T., Hamasaki, H., Wakabayashi, T., & Saito, R.
(2025). Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice. Neurology International, 17(5), 62.
https://doi.org/10.3390/neurolint17050062
